Data about FDA special protocol assessments might help public

02/9/2010 | Forbes

Though the FDA promised to be more transparent, legislation might be necessary to require the agency to disclose special protocol assessments with drugmakers, according to this blog. By making SPAs public, investors can become aware of the progress of drug trials, raising their confidence in their investments, the blog notes. Because the FDA treats SPAs as confidential, investors of Cell Therapeutics were unaware that the company's SPA was no longer valid, causing shares to drop 40% on Monday.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ